SDM - News

2026-01-07

SDM's Beijing and Hangzhou Laboratories Secure Multiple Proficiency Test Recognitions from Chinese Authorities

The outstanding performance of both Beijing Shouyan and Hangzhou Amador laboratories in the proficiency testing conducted by NIFDC and SCCL represents recognition from authoritative industry certification systems of SDM’s capabilities and quality control system. This system ensures that laboratories across different locations consistently deliver high-quality, reliable data in compliance with any authoritative audit.

MORE >

2025-12-11

Prodegre Initiates IIT for world’s First Peptide-Based Protein Degrader PDR-001 at Ruijin Hospital – SDM Providing Full CRO Support

PDR-001, the world's first new drug for Parkinson's disease, has launched clinical trials and completed the first enrollment! The drug uses an innovative peptide degradation structure and targets the core pathogenic protein α-synuclein, which is an important breakthrough in the field of neuroscience. As the CRO of this project, SDM is honored to be deeply involved and looks forward to continuing to work closely with all parties to jointly promote the early launch of this innovative treatment originally developed in China and benefit patients around the world!

MORE >

2025-11-22

SDM Sponsors A Workshop on Cell & Gene Therapy Development in Guangzhou

The High-Quality Development Seminar on the Greater Bay Area's Cell and Gene Industry concluded successfully on November 21st! Stem Pharm comprehensively demonstrated its integrated service capabilities and cutting-edge layout in the field of cell and gene therapy during the seminar. Multiple senior executives of Stem Pharm attended the event, joining hands with industry partners to explore the coordinated development of cell and gene therapy (CGT) in the Greater Bay Area.

MORE >

2025-10-28

Jing Medicine's Next-Generation EGFR PROTAC Program Clears U.S. FDA for Clinical Trials | Backed by SDM

SDM Bioservices, serving as Jing Medicine’s regulatory strategy partner, played a pivotal role in the successful FDA application process. Leveraging deep expertise in global regulatory affairs, SDM delivered comprehensive GAP analysis, technical document preparation, and submission management services. SDM also supported Jing Medicine’s IND application in China, establishing a robust foundation for the program’s global development strategy.

MORE >

2025-10-14

Dr. Weishihu Joins SDM as Deputy General Manager of Medical & Pharmacovigilance for Early Clinical Business Unit

Beijing, October 14, 2025 – SDM, a one-stop clinical development CRO, today announced that Dr. Weishihu has joined the company as Deputy General Manager of Medical and Pharmacovigilance for the Early Clinical Business Unit. He will be fully responsible for developing and managing the company's early clinical development medical strategies and pharmacovigilance systems.

MORE >

News

News

SDM's Beijing and Hangzhou Laboratories Secure Multiple Proficiency Test Recognitions from Chinese Authorities

Prodegre Initiates IIT for world’s First Peptide-Based Protein Degrader PDR-001 at Ruijin Hospital – SDM Providing Full CRO Support

SDM Sponsors A Workshop on Cell & Gene Therapy Development in Guangzhou

Jing Medicine's Next-Generation EGFR PROTAC Program Clears U.S. FDA for Clinical Trials | Backed by SDM

Dr. Weishihu Joins SDM as Deputy General Manager of Medical & Pharmacovigilance for Early Clinical Business Unit

Last Name：